A detailed history of Rhumbline Advisers transactions in Pds Biotechnology Corp stock. As of the latest transaction made, Rhumbline Advisers holds 11,537 shares of PDSB stock, worth $38,879. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11,537
Previous 34,996 67.03%
Holding current value
$38,879
Previous $138,000 76.09%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 01, 2024

SELL
$2.55 - $4.02 $59,820 - $94,305
-23,459 Reduced 67.03%
11,537 $33,000
Q1 2024

May 09, 2024

BUY
$3.85 - $6.59 $4,623 - $7,914
1,201 Added 3.55%
34,996 $138,000
Q4 2023

Feb 08, 2024

BUY
$3.95 - $6.58 $5,059 - $8,428
1,281 Added 3.94%
33,795 $167,000
Q3 2023

Nov 09, 2023

BUY
$4.8 - $6.4 $7,248 - $9,664
1,510 Added 4.87%
32,514 $164,000
Q2 2023

Aug 08, 2023

BUY
$5.03 - $9.9 $155,950 - $306,939
31,004 New
31,004 $155,000

Others Institutions Holding PDSB

About PDS Biotechnology Corp


  • Ticker PDSB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,458,700
  • Market Cap $95.9M
  • Description
  • PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies...
More about PDSB
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.